- $2.77bn
- $2.28bn
- $652.50m
- 66
- 15
- 50
- 40
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 143 | 227 | 378 | 547 | 653 |
Cost of Revenue | |||||
Gross Profit | 123 | 198 | 340 | 491 | 588 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 262 | 403 | 644 | 955 | 923 |
Operating Profit | -120 | -176 | -265 | -408 | -270 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -118 | -210 | -285 | -403 | -253 |
Provision for Income Taxes | |||||
Net Income After Taxes | -119 | -212 | -288 | -408 | -257 |
Net Income Before Extraordinary Items | |||||
Net Income | -119 | -212 | -288 | -408 | -257 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -119 | -212 | -288 | -408 | -257 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.759 | -1.24 | -1.63 | -2.01 | -1.15 |
Dividends per Share |